This observational study aims to understand how well a special model can predict early signs of mild cognitive impairment (MCI) due to Alzheimer's disease. You might be eligible if you are 55 or older, have at least one APOE ε4 gene (a genetic risk factor for Alzheimer's), and have existing whole-genome sequencing data. The study is looking at how well a combination of genetic information, blood tests, and digital monitoring (like sleep and activity tracking) can predict if someone who is currently cognitively normal or very mildly impaired will develop early MCI within two years. The main goal is to see if this model can accurately predict the conversion to a state where a specific blood marker (pTau217) becomes positive, indicating Alzheimer's-related changes.

Study design

This is an observational study following about 100 participants over two years. It is not testing a new treatment but rather observing how different factors predict the development of early mild cognitive impairment.

What's involved

You would be followed over two years, providing existing whole-genome sequencing data and potentially participating in digital monitoring.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 0-24 months to observe the conversion from cognitively normal to pTau217-positive.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.